Y-mAbs Therapeutics, Inc.’s Post

Clario’s commitment to patient safety is at the core of our oncology drug development strategy. With involvement in 70+ novel oncology drug approvals in the past decade, we know the challenges inherent in oncology trials and can provide critical insights on safety endpoints. Trust Clario’s centralized approach to data collection and robust consulting on strategic study design to put your trial in the best position for success. Are you ready to see what makes Clario an end-to-end partner in oncology? See our full capabilities for oncology at https://hubs.li/Q028wwV-0 #ClinicalTrials #Oncology

Great article from FirstWord with Loxo@Lilly EVP Jacob Van Naarden on their ambitions for targeted radiopharmaceuticals: https://lnkd.in/eR9grXD6 I took away 3 key success factors for a targeted radiopharmaceutical franchise: -Assurance of radionuclide supply (either through manufacturing or supply chain relationships) and contingent upon radionuclide supply and other factors, the ability for manufacturing to meet demand -Radionuclide diversity, both to hedge against supply constraints as well as to address different therapeutic goals (also discussed here: https://lnkd.in/ecDEsU5y) -Breadth of targets / tumor types in the clinical development plan (also discussed in the article mentioned above)

Don’t miss our latest white paper, where experts from IQVIA and Radialogica define the key elements of a radiation therapy quality management program, and provide a guideline for practical prospective implementation into pharmaceutical clinical trials. Download now. https://bit.ly/48LrdOb #radiationtherapy #clinicaltrials #oncology

M&A news has been in full swing, & this week marks yet another big move- Biotech company Bristol Myers Squibb has announced its acquisition of Mirati Therapeutics. Mirati, a cancer drug developer, has been purchased for a whopping $5.8B. 💲💲 This move marks a larger trend of drug developers making big investments in immuno-oncology, as this field has been rapidly growing in the past few years. #BMS is no stranger to investments, as the company has been investing heavily in #biopharmaceuticals, making sure to stay ahead of the competition in this ever-evolving field. 📈📈 The acquisition of Mirati Therapeutics will also bring more products to Bristol Myers Squibb portfolio, something that the company is extremely excited about. This move is part of BMS's larger strategy of expanding its oncology portfolio, & the company is confident that this acquisition will help them achieve their goals. This is yet another example of an innovative company taking the initiative to stay ahead of the game. 🤩 With this move, BMS is clearly showing that they are committed to staying at the top of the immuno-oncology market. #BMS #Mirati #IOncology

Unlock the future of oncology research with TriNetX! Our team collaborates with leading medical experts and pharmaceutical innovators to design representative database specifications that align with your study needs. Discover how our tailored approach enhances your research outcomes. https://ow.ly/AOxQ50SpsfJ #Oncology #ClinicalResearch #RealWorldData

Explore our latest white paper, a collaborative effort between IQVIA and Radialogica experts. This paper outlines the crucial components of a radiation therapy quality management program and offers a practical guide for its implementation in pharmaceutical clinical trials. Download your copy now! 📥 https://bit.ly/48LrdOb #RadiationTherapyInnovation #ClinicalTrialAdvancements #OncologyResearch #PharmaTrends #QualityManagement #ExpertInsights 🌐💡🔬📊🧬🩺🔍

I'm thrilled to share this insightful article from Nature with you. It's a must-read for anyone interested in the latest developments in science and technology of ADCs. The article "The Antibody-Drug Conjugate Landscape" delves into the world of antibody-drug conjugates (ADCs), which have become a vital therapeutic approach in the field of oncology due to their superior clinical profiles compared to standard chemotherapy. The article forecasts the revenue from approved ADCs and those in phase III development to reach $26 billion in 2028. However, the long-term growth of ADCs faces challenges due to limited validated payload mechanisms of action and non-specific payload delivery issues. The article explores the impact of next-generation ADC technology in addressing these challenges, categorizing ADC assets in development into two types and providing specific examples of innovative ADCs in the clinical pipeline. Additionally, the article assesses next-gen targets and technology, highlighting the potential impact of ADC innovation and the need for diverse collections of components to enable tailored development for specific targets and indications.

📢 Presenting Sidvim Regulatory Digest – January 2024 Edition! 📰   Stay updated on the latest Pharma regulatory changes with our concise summary. This week we cover the topic of " Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics " 💊   Stay ahead of the game and stay informed with Sidvim Lifesciences Regulatory Digest. #PharmaRegulation #Oncodrugs

Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with #immunotherapy drugs improves patient survival more than #chemotherapy alone for pleural mesothelioma. Study researchers used pembrolizumab (Keytruda) alongside #platinum and #pemetrexed chemotherapy. Christina S. Baik, MD, MPH, reviewed the phase 3 trial results during the American Society of Clinical Oncology’s 2023 Best of ASCO Seattle annual meeting. #Avanscure #bulkAPI #bulkdrugs #cancertreatment #oncology Enquire about Pemetrexed Disodium at sales@avanscure.com or visit https://lnkd.in/dJfAKmkH

Bopa Moruo Private Equity and RMB Ventures have invested in Icon Oncology, South Africa’s leading cancer treatment provider. Icon provides radiotherapy, chemotherapy and oncology managed care services. Icon have a national footprint of 26 radiotherapy facilities with 30 cutting-edge linear accelerators, enabling high quality care for 30,000 patients annually across the network. Icon manages 59 approved chemotherapy facilities, a licensed pharmaceutical distributor and three compounding pharmacies. Bopa Moruo is proud to invest its financial, intellectual and social capital in innovative healthcare. This is Transformational Capital at work. Read more at https://lnkd.in/djp6AaQH   #CorporateFinance #TransformationalCapital #Healthcare #PrivateEquity